Persistent problems with false positive results were encountered when carrying out a published RT-PCR method to detect the CBF␤/MYH11 transcripts associated with the inv(16)(p13q22) cytogenetic abnormality in acute myeloid leukaemia. These were shown to be due to amplification of part of the intronic MYH11 sequence, presumably from very small amounts of contaminating DNA or unspliced primary RNA transcripts, amplified because of partial homology of the CBF␤3 primer to intronic MYH11 sequence.
Introduction
Cytogenetic findings at diagnosis of acute leukaemia can provide powerful prognostic indications. Chromosomal rearrangements inv(16)(p13q22) and t(16;16)(p13;q22) are closely associated with acute myeloid leukaemia (AML) FAB subtype M4Eo. 1 The resulting CBF␤/MYH11 fusion mRNA, which disrupts the MYH11 gene (16p13) and CBF␤ gene (16q22) 2 can be detected by the reverse transcription polymerase chain reaction (RT-PCR). 3 It has been suggested that the presence of inv(16) confers a favourable prognosis in which patients have longer disease-free survival, leading to the suggestion that they do not require a bone marrow transplant in first remission. 4 Recently Langabeer et al 5 patients unlikely to carry the rearrangement (Table 1) . We detected the expected 209 bp band representative of the CBF␤/MYH11 transcript in all four cytogenetically positive samples. However, in AML samples cytogenetically negative for the inv(16) and in eight of 10 control samples a similar band suggesting a positive result was seen in some assays. We have identified this as an anomalous RT-PCR product from the non-rearranged MYH11 gene.
Materials and methods
Bone marrow samples were separated on lymphoprep (Nycomed, Oslo, Norway) and total cellular RNA was extracted from 5 × 10 6 cells using 1.5 ml TRIzol (Gibco BRL, Paisley, UK) following the manufacturer's instructions. This method was used because of its simplicity for storage of samples upon receipt, only some of which would require subsequent RNA extraction. RNA was redissolved in 25-50 l of sterile distilled water. The presence of any contaminating DNA in the RNA preparations was tested for as described by Lion 6 using primers from the ABL proto-oncogene which span the 0.6 kb intron 2 and generate different-sized products from DNA and RNA templates.
Preparation of cDNA and PCR amplification was carried out according to the procedure described by Langabeer et al. 5 Following the generation of apparently false positive PCR products and the amplification of a band of the same size as the CBF␤/MYH11 fusion gene product from a control sample of genomic DNA (Table 1) , specific CBF␤/MYH11 fusion transcripts were distinguished from false positives by cleavage of the RT/PCR product with the restriction enzyme BanII. Ten l of the second round RT-PCR products were digested for 5 h at 37°C in a volume of 20 l containing 5 units of BanII restriction enzyme (New England Biolabs, Hitchin, UK) and the manufacturer's buffer. The products were visualised by agarose gel electrophoresis and ethidium bromide staining. CBF␤/MYH11 fusion transcripts give two cleavage fragments of 81 bp and 128 bp.
Single-stranded conformational polymorphism (SSCP) analysis of PCR products was carried out using standard methodology. The base sequences of the PCR products were determined using standard methodology and an ABI 377 fluorescence activated sequencer (Applied Biosystems, Warrington, UK). Number of positive, false positive and negative RT-PCR results per single patient sample using the method described by Langebeer et al. 
Results and discussion

Using the Langabeer et al's
5 amplification protocol we detected the expected 209 bp band representative of the CBF␤/MYH11 fusion transcript in all four cytogenetically positive samples. However, in three non-inv(16) AML samples and in eight of 10 control samples a similar band suggesting a positive result was seen in at least one assay (Table 1) . On further investigation SSCP analysis of the fragments amplified from inv(16) positive samples showed different patterns from those of the controls and the AML samples cytogenetically negative for the inv(16). Sequence analysis showed that the fragment amplified from inv(16) positive samples matched the published 209 bp sequence of the most common CBF␤/MYH11 transcript. However, the sequence of the PCR product in the control samples was different. Use of the BLAST N programme to search various genome databases on the World Wide Web revealed the abnormal PCR product to be a 210 bp fragment spanning intron 30, the site of the major breakpoint cluster region in inv(16), and exon 31 of the MYH11 gene (16p13). On analysis of the primer sequences we found a 7 bp sequence at the 3′ end of primer CBF␤3 which was homologous to a sequence within intron 30 of MYH11 (Figure 1) . By using genomic DNA as a substrate we produced the same 210 bp band in two out of five assays. The template RNA must therefore have been contaminated with DNA or unspliced primary transcript RNA, although contamination must have been at a low level because it was undetectable using the ABL proto-oncogene primers described by Lion.
We identified a BanII restriction enzyme site which was present in the CBF␤/MYH11 fusion gene transcript but not in the 210 bp MYHII product thus enabling verification of positive results in the four cytogenetically positive inv(16) AML patients (patients 1-4, Table 1 ).
In conclusion, we have found that the method described by Langabeer et al 5 may amplify a 210 bp fragment either from unspliced primary RNA transcripts or possibly from small quantities of contaminating DNA, resulting in a false positive result when visualised by agarose gel electrophoresis. Alternative primers to CBF␤3 are available 7, 8 and should be used to avoid this problem. Given that low level DNA contamination is a recognised problem in RNA purification, false positive results may have previously gone undetected. In view of the diagnostic importance of the finding of an inv(16) fusion product we suggest that all samples previously shown to be positive by RT-PCR analysis using the CBF␤3 primer and uncorroborated by cytogenetic analysis should be reanalysed using alternative primers, or if the PCR products are still available, verified by BanII restriction enzyme digestion or sequencing.
